Richard Lehman’s journal review—11 November 2013
NEJM 7 Nov 2013 Vol 369 1783 When you’ve already tried dasatinib and nilotinib, should your thoughts be turning to ponatinib? In case you’re wondering what I’m talking about, these […]
Search Results for: richard lehman blog
Richard Lehman’s journal review—4 November 2013
JAMA Intern Med 28 Oct 2013 Vol 173 1770 There is very little in the journals this week: JAMA is taking a week off and even JAMA Intern Med has […]
Richard Lehman’s journal review—28 October 2013
NEJM 24 Oct 2013 Vol 369 1577 Two years ago I unexpectedly found myself in the USA amongst good and great people who were determined to open up hidden data […]
Richard Lehman’s journal review—21 October 2013
NEJM 17 Oct 2013 Vol 369 1491 “Tiotropium (Spiriva, Boehringer Ingelheim), a long-acting inhaled anticholinergic bronchodilator, improves lung function, quality of life, and exercise endurance and reduces exacerbations in patients […]
Richard Lehman’s journal review—14 October 2013
NEJM 10 Oct 2013 Vol 369 1395 It’s been known for at least four thousand years that the heart has two ventricles, but what they actually did was a source […]
Richard Lehman’s journal review—7 October 2013
NEJM 3 Oct 2013 Vol 369 1295 The human birth canal, it has often been observed, is not particularly well designed for the passage of one baby, let alone two. […]
Richard Lehman’s journal review—30 September 2013
NEJM 26 Sep 2013 Vol 369 1195 Gosh, I feel vulnerable. The opening paper in this week’s New England Journal is about sources of C difficile infection in “healthcare settings […]
Richard Lehman’s journal review—23 September 2013
NEJM 19 Sep 2013 Vol 369 1106 I’m starting with the second paper about colonic cancer screening in this week’s New England Journal of Medicine, because it takes us to […]
Richard Lehman’s journal review—16 September 2013
NEJM 29 Aug-12 Sep 2013 Vol 369 799 When comparing a new fixed-dose anticoagulant with conventional warfarin based anticoagulation, what do you look for? Thrombotic events, death, major bleeding? Yes, […]
Richard Lehman’s journal review—27 August 2013
NEJM 22 Aug 2013 Vol 369 699 Vedolizumab. What a name for an important new drug. Just remember the vedo bit and the fact that it’s a monoclonal antibody, and […]